Christopher D. Bahl, MS, PhD is a protein designer, biochemist and structural biologist. Chris pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with David Baker at the Institute for Protein Design in Seattle. In 2017, Chris joined the Institute for Protein Innovation in Boston as one of the founding faculty members, with co-appointments at Boston Children's Hospital and Harvard Medical School. In 2021, Chris and members of his laboratory left academia together to found AI Proteins, Inc., where Chris currently serves as the President and Chief Scientific Officer. AI Proteins is leveraging the power of miniproteins to rapidly create novel therapeutics de novo, a game-changing approach with the potential to transform the pharmaceutical industry.
Speaking In
4:45 PM - 5:00 PM
Wednesday, June 7
